Ataxin-1 Monoclonal Antibody

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted

Introducing the ATAXIN-1 Monoclonal Antibody, a cutting-edge biotechnological product designed to revolutionize the field of neurodegenerative disease research. This meticulously crafted antibody is specifically engineered to target and bind to the ATAXIN-1 protein, a key player in the pathogenesis of spinocerebellar ataxia type 1 (SCA1).

With utmost precision and efficacy, the ATAXIN-1 Monoclonal Antibody exhibits exceptional affinity towards its target, enabling researchers to accurately detect and quantify ATAXIN-1 protein levels in various biological samples. Its monoclonal nature ensures consistent and reproducible results, guaranteeing reliability in experimental outcomes.

Crafted through rigorous scientific methodologies, this antibody boasts exceptional specificity, exhibiting minimal cross-reactivity with other proteins, thereby minimizing any potential confounding factors. Its high sensitivity allows for the detection of even trace amounts of ATAXIN-1, facilitating comprehensive investigations into the molecular mechanisms underlying SCA1.

The ATAXIN-1 Monoclonal Antibody is meticulously validated through stringent quality control measures, ensuring its reliability and reproducibility across diverse experimental conditions. Its exceptional stability and long shelf life further enhance its utility, enabling researchers to conduct experiments at their convenience without compromising the antibody's performance.

This groundbreaking product serves as an invaluable tool for researchers dedicated to unraveling the complexities of SCA1 and other related neurodegenerative disorders. By facilitating precise and accurate detection of ATAXIN-1 protein, the ATAXIN-1 Monoclonal Antibody paves the way for novel insights into disease mechanisms, potential therapeutic targets, and the development of innovative treatment strategies.

Choose the ATAXIN-1 Monoclonal Antibody to elevate your research endeavors to unprecedented heights, as you delve deeper into the intricate world of neurodegenerative diseases.